Hims & Hers expands into unapproved peptides
HIMS
Statements (4)
- Neutral
Hims & Hers launches new peptide treatments including sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine
- Neutral
Hims & Hers launched Peptides+, a new specialty for personalized, proactive health.
- Neutral
The HHS committee voted 8-6 to expand access to six unproven peptides including BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
- Bullish
Hims stock increased on a Health Department push to legalize six peptides.